Troy Wuertz
@Ikarian Capital, Llc
Latest period2024 - Q3ReportedManaged Assets$717.154MTotal holdings121
Assets growth rate24.93%Assets growth rate (2-Q avg)-6.06%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Ikarian Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 121 positions.
Assets under management
The assets under management (AUM) of Ikarian Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 717.154M in assets, with a quarterly growth rate of 24.93% and a 2-quarter average growth rate of -6.06%. The portfolio is managed by Troy Wuertz, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CRNXCrinetics Pharmaceuticals In
| 3.05% | $21.815M 426,913 shares@ $51.11 avg price | Decreased -27.49% |
SLNOSoleno Therapeutics Inc
| 2.34% | $16.734M↑ Call 331,437 shares@ $50.5 avg price | Decreased -25.59% |
ELVNEnliven Therapeutics Inc
| 1.78% | $12.759M 499,566 shares@ $25.54 avg price | Decreased -14.83% |
CPRXCatalyst Pharmaceuticals Inc
| 1.16% | $8.307M 417,850 shares@ $19.88 avg price | Decreased -19.39% |
BBIOBridgebio Pharma Inc
| 1.02% | $7.272M 285,613 shares@ $25.46 avg price | Decreased -15.5% |
SRPTSarepta Therapeutics Inc
| 0.95% | $6.766M 54,176 shares@ $124.9 avg price | Decreased -73.52% |
NRIXNurix Therapeutics Inc
| 0.82% | $5.842M 260,000 shares@ $22.47 avg price | Decreased -40.97% |
NUVLNuvalent Inc
| 0.75% | $5.344M 52,238 shares@ $102.3 avg price | Decreased -65.54% |
PYXSPyxis Oncology Inc
| 0.68% | $4.83M↑ Call 1.316M shares@ $3.68 avg price | Decreased -21% |
WVEWave Life Sciences Ltd
| 0.63% | $4.463M 544,265 shares@ $8.2 avg price | Decreased -5.35% |